Neurocrine Biosciences Inc., of San Diego, priced an underwritten public offering 9.5 million shares of common stock at $8. 10 per share, a 6.25 percent discount to Wednesday's closing price, for gross proceeds of $77 million. Read More
The irony of melanoma drug Zelboraf (vemurafenib, Roche AG and Daiichi Sankyo Co. Ltd.) is its side-effect profile. In 15 percent to 30 percent of patients treated with the drug, "you give a pill to treat a skin cancer and all of a sudden, another skin cancer appears," Antoni Ribas told BioWorld Today. Read More
WASHINGTON – Even with all the Capitol Hill finger pointing over the continuing U.S. drug shortage crisis, one culprit has been largely overlooked – increased demand for commonly used cancer drugs such as cisplatin, doxorubicin and paclitaxel. Read More
• Genta Inc., of Berkeley Heights, N.J., reported results from its Phase IIb confirmatory trial of tesetaxel in 41 patients with advanced gastric cancer who progressed on at least one prior chemotherapy regimen that included a platinum compound (cisplatin, oxaliplati or carboplatin) and a fluoropyrimidine compound (5-fluorouracil or capecitabine [Xeloda, Hoffman-La Roche]). Read More
• Innovative Targeting Solutions Inc., of Burnaby, British Columbia, initiated a research collaboration allowing Amgen Inc., of Thousand Oaks, Calif., to assess its human antibody technology (HuTARG) for a broader potential collaboration. The mammalian technology generates antibody diversity in vitro via RAG1/RAG2-mediated V(D)J recombination. Terms were not disclosed. Read More
